The Direct Medical Care Costs Associated with Gastric Cancer in a Third-level Hospital in Iran
AbstractAbstract Background: Approximately 20 million individuals with cancer are living in the world. Gastric cancer is the fourth leading cause of death in the world. The aim of this study was to evaluate the costs of direct medical care of gastric cancer patients in a tertiary teaching hospital in Iran. Methods: The present study is a descriptive-analytical, which has been done in two main stages. The first stage was done by the aim of designing a form based on the valid international guidelines. The second step was done to identify the costs of diagnosis and treatment of Gastric cancer. To analyze the costs data, descriptive statistics such as mean and standard deviation were utilized. According to the violation of the assumption of normalization of the data, nonparametric statistical tests such as Mann-Whitney, Wilcoxon and SPSS 16 were used for data analysis. Results: In this research, the records of 449 gastric cancer patients who referred to Omid tertiary teaching Hospital in Mashhad from the year 2005 to 2015 were studied. According to the results, the hospitalization costs has the highest average costs. Based on the signification level of the Mann Whitney test, no remarkable difference can be seen in the total costs of metastatic and non-metastatic patients (P-value: P> 0.05). Conclusion: In addition, new policies to reduce the heavy costs of these patients, which are performed by insurance agencies, financial supports from financial institution and charities and etc. can reduce the financial barriers for patients and prevent them from meeting catastrophic costs.
Sierra MS, Cueva P, Bravo LE, Forman D. Stomach cancer burden in Central and South America. Cancer epidemiology. 2016;44 Suppl 1:S62-s73.
Amani F, Sadrkabir M, Saeid Sadeghieh Ahari, Barzghari S, Yazdanbod A, Sabzevari A, et al. Epidemiology of Gastric Cancer in Northwest Iran: 2003-2011. Middle East Journal of Cancer. 2015;6(3):189-93.
Stewart B, Wild C. World Cancer Report 2014, International Agency for Research on Cancer, Lyon, France,
Berraho M, Najdi A, Mathoulin-Pelissier S, Salamon R, Nejjari C. Direct Costs of Cervical Cancer Management in Morocco. Asian Pacific Journal of Cancer Prevention. 2012;13:3159-63.
Rahman R, Asombang AW, Ibdah JA. Characteristics of gastric cancer in Asia. World journal of gastroenterology. 2014;20(16):4483-90.
Renee A. pharmacoeconomics from theory to practice edited by: health economics and managment solutions; 2010.
Akbarzadeh A, Esmaeily M, Kimia-Far K. Medical Information Management and estimate direct medical costs of lung cancer. Medical Information Management. 2008;5(2):151-8.
Haga K, Matsumoto K, Kitazawa T, Seto K, Fujita S, Hasegawa T. Cost of illness of the stomach cancer in Japan-a time trend and future projections. BMC health services research. 2013;13(1):1.
Chodick G, Porath A, Alapi H, Sella T, Flash S, Wood F, et al. The direct medical cost of cardiovascular diseases, hypertension, diabetes, cancer, pregnancy and female infertility in a large HMO in Israel. Health Policy. 2010;95(2-3):271-6.
Varvasovszky Z, Brugha R. A stakeholder analysis. Health policy and planning. 2000;15(3):338-45.
Burton A, Osborn D, Atkins L, Michie S, Gray B, Stevenson F, et al. Lowering Cardiovascular Disease Risk for People with Severe Mental Illnesses in Primary Care: A Focus Group Study. PLoS One. 2015;10(8):e0136603.
Sharma P, Dunn RL, Wei JT, Montie JE, Gilbert SM. Evaluation of point-of-care PRO assessment in clinic settings: integration, parallel-forms reliability, and patient acceptability of electronic QOL measures during clinic visits. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2016;25(3):575-83.
Winwood PW, Pritchard HJ. Tapering Practices of Strongman Athletes: Test-Retest Reliability Study. 2017;6(10):e211.
Nourozinia F, Rasmi Y, Otarod M, Golizadeh M, Khadem-Ansari M-H. Epidemiology And Histopathology Of Gastric Cancer In Urmia. URMIA MEDICAL JOURNAL. 2013;24(3):170-5.
vahedi m, Moghimi-Dehkordi B, Safaee A, Pourhoseingholi A. Cost analysis of upper gastrointestinal diseases in Tehran Province: a population-based study, 85-1384. Kermanshah University of Medical Sciences. 1391;16(6):457-65.
Yoritaka A, Fukae J, Hatano T, Oda E, Hattori N. The Direct Cost of Parkinson Disease at Juntendo Medical University Hospital, Japan. Internal Medicine. 2016;55(2):113-9.
Hasoumi M, Nasehi M, Khakian M, Mohseni M, Ziaiifar H, Keykale MS. Cost of Illness of Tuberculosis in Tehran in the Year 2011. Materia socio-medica. 2014;26(5):339.
Ng CS, Toh MPHS, Ko Y, Lee JY-C. Direct medical cost of type 2 diabetes in Singapore. PloS one. 2015;10(3):e0122795.
Bending MW, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J, et al. Estimating the direct costs of bowel cancer services provided by the National Health Service in England. International journal of technology assessment in health care. 2010;26(4):362-9.
Zarogoulidou V, Panagopoulou E, Papakosta D, Petridis D, Porpodis K, Zarogoulidis K, et al. Estimating the direct and indirect costs of lung cancer: a prospective analysis in a Greek University Pulmonary Department. Journal of thoracic disease. 2015;7(Suppl 1):S12.
Legorreta AP, Brooks RJ, Leibowitz AN, Solin LJ. Cost of breast cancer treatment. A 4-year longitudinal study. Arch Intern Med. 1996;156(19):2197-201.